Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Boston Medical Group vs OurView Health

Boston Medical Group
Graded #279

Lower grade

vs+5.699999999999996
OurView Health
Graded #162

Higher grade

The verdict

OurView Health takes it — 67.6/100 to 61.9/100.

OurView Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. OurView (OurView Health) is a 100% online multi-vertical telehealth service with an Our View Savings Club membership offering pharmacy-direct pricing on U.S.-compounded medications.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOurView Health +22
54
76
Dose & formulationOurView Health +12
52
64
Clinical oversightBoston Medical Group +10
89
79
Labs & monitoringEven
53
53
FulfillmentOurView Health +5
65
70
Contract termsBoston Medical Group +10
55
45
Boston Medical Group · left barOurView Health · right bar

The numbers

MetricBoston Medical GroupOurView Health
WeighScore61.9/10067.6/100
GradeCC
Scorecard rank#279#162
Semaglutide$199/mo (starting strength, rising with dose, compounded)$75/mo (starting dose, compounded)
TirzepatideNot disclosed$135/mo (starting dose, compounded)
Coverage7 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Boston Medical Group

Graded #279 · C

Strengths

  • An established medical group with a defined 12-week programme rather than an open-ended subscription
  • The price range and the 12-week total are both published, once you reach the costs page
  • Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight

Where it loses points

  • The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
  • The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
  • The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
  • Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
OurView Health

Graded #162 · C

Strengths

  • Low starting prices via the Savings Club — compounded semaglutide from $75, tirzepatide from $135
  • Clear product pricing with no contracts; medication shipped to your door (30-day supply)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, Returns & Refunds)
  • Discloses meds are compounded by a licensed third-party pharmacy; multi-vertical (TRT, HRT, BHRT, peptides)

Where it loses points

  • A comparison table on the site quotes $90 'without membership' against $75 'with membership' while the product cards say 'No membership' and the cart charges $75 without one — the provider contradicts itself on whether a membership exists
  • Both figures are starting-dose rates; the cost of a titrated dose is published as a ladder rather than a single price
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard